Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04420156 · ClinicalTrials.gov registry record
Clinical and Genetic Analysis of ROP
A clinical trial of Retinopathy of Prematurity, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 5
- Study locations
NCT04420156 is a study of Retinopathy of Prematurity that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 2,000 participants, above the 83-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (2310% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT04420156, a study of Retinopathy of Prematurity, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 5
- Study locations
Study Summary
Retinopathy of Prematurity (ROP) is a vascular disease affecting the retinas (back of the eye) of low birth weight infants. Although it can be treated effectively if diagnosed early, it continues to be a leading cause of childhood blindness in the United States and throughout the world. The investigators feel that this study will result in specific knowledge discovery about ROP, as well as general knowledge about how image-based data and genetic data can be combined to better understand clinical disease. Participants will be recruited from the neonatal intensive care unit (NICU) at OHSU, along with 4 collaborating institutions (William Beaumont Hospital, Stanford University, University of Illinois Chicago and University of Utah). Hospitalized infants who receive ROP screening examinations for routine care will be eligible for this study, and will be offered the opportunity to participate. Subjects who provide informed consent will have clinical data from routine care collected along with demographic characteristics, results from routine ROP screening examinations, presence of systemic disease or risk factors. Retinal photographs will be taken during these routine eye exams, using a commercially-available camera that has been FDA-cleared for taking pictures from retinas of premature infants. These retinal pictures do not contain any identifiable patient information, and are taken as routine standard of care. The long-term goal of this research is to establish a quantitative framework for retinopathy of prematurity (ROP) care based on clinical, imaging, genetic, and informatics principles. The investigators have previously recruited and rigorously phenotyped and genotyped a large study cohort, including implementation of a novel reference standard diagnosis; and built a world-class research consortium for image, genetic, and bioinformatics analysis.
Conditions Studied
Interventions
- OTHER No intervention administered.
Study Locations (5)
California
- Stanford University - Palo Alto
Illinois
- University of Illinois Chicago - Chicago
Michigan
- William Beaumont Hospital - Royal Oak
Oregon
- Oregon Health & Science University - Portland
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2011-07-01 |
| Est. Completion | 2030-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04420156
The ClinicalTrials.gov registry entry for NCT04420156 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 83-participant average among 7 other Retinopathy of Prematurity trials with a reported enrollment target (2310% higher). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinopathy of Prematurity appearing as the primary indexed condition, and to 1 intervention - of which No intervention administered. is the first listed.
NCT04420156 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Michigan.
Frequently Asked Questions
What is clinical trial NCT04420156 about?
NCT04420156 is a clinical study titled "Clinical and Genetic Analysis of ROP". Retinopathy of Prematurity (ROP) is a vascular disease affecting the retinas (back of the eye) of low birth weight infants. Although it can be treated effectively if diagnosed early, it continues to be a leading cause of childhood blindness in the United States and throughout the world. The investig...
What is the current status of trial NCT04420156?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2011-07-01. Estimated completion is 2030-05-31.
What conditions does trial NCT04420156 study?
This clinical trial studies the following conditions: Retinopathy of Prematurity.
What interventions are being tested in trial NCT04420156?
The interventions under investigation include: No intervention administered. (OTHER).
Who is sponsoring clinical trial NCT04420156?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04420156 being conducted?
This trial has 5 study locations across California, Illinois, Michigan, Oregon, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinopathy of Prematurity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Retinal Vasculature in Infant Eyes
RECRUITING
-
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
RECRUITING · NA
-
Bevacizumab Treatment For Type 1 ROP
ACTIVE NOT RECRUITING · Phase 2
-
Validation of i-ROP DL to Detect More Than Mild ROP
ACTIVE NOT RECRUITING · NA
-
Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)
ACTIVE NOT RECRUITING
-
The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.